BioLineRx Ltd. and Hemispherian AS issued an 8-K-style press release on November 16, 2026, announcing the presentation of two GLIX1 posters at the 31st Society for Neuro-Oncology Annual Meeting and disclosing that dosing had been initiated in the fourth cohort of the ongoing Phase 1/2a clinical study.

Key Highlights

  • Fourth cohort initiated: Dosing has begun in the fourth cohort of the open-label, multicenter Phase 1/2a study (NCT07464925), according to the filing.
  • No significant safety concerns: The filing states that "no significant treatment-emergent adverse events have been observed" in the study to date.
  • Window-of-opportunity cohorts planned: Remaining cohorts will include patients in a window-of-opportunity setting to directly assess GLIX1 brain penetration and biological activity in human tumor tissue.
  • Brain penetration confirmed in preclinical model: GLIX1 was detected in the brain at all tested dose levels following oral administration, with total exposure increasing at higher doses, in the orthotopic U87MG model.
  • Activity in TMZ-resistant model: In the BN2276 PDX model, GLIX1 demonstrated tumor growth inhibition compared to control, while temozolomide was not effective, according to the filing.
  • Dose-dependent pharmacodynamic marker: GLIX1 produced dose-dependent increases in tumor genomic 5-hydroxymethylcytosine (5hmC), described as a marker of TET2 activity, which correlated with tumor growth inhibition.
  • Phase 1/2a trial initiated in Q1 2026: According to the filing, the Phase 1/2a clinical trial was initiated in the first quarter of 2026.

GLIX1 Preclinical and Clinical Data Presented at SNO 31st Annual Meeting

BioLineRx (NASDAQ:BLRX) and partner Hemispherian AS disclosed on November 16, 2026, that two posters on GLIX1, described in the filing as a "first-in-class, oral, brain-penetrant TET2 activator," were presented at the 31st Society for Neuro-Oncology Annual Meeting. The clinical poster (CTNI-25) described the design of study NCT07464925, an open-label, multicenter, first-in-human dose-escalation study followed by a dose-expansion phase. The study is designed to determine the recommended dose of GLIX1 as monotherapy based on safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with high-grade diffuse glioma whose disease has progressed or recurred following prior therapies.

The filing reports that dosing has been initiated in the fourth cohort and that no significant treatment-emergent adverse events have been observed. Future cohorts, the filing states, will include patients in a window-of-opportunity setting, which the companies say is expected to provide information on GLIX1 exposure and biological activity in human brain tumor tissue. Philip Serlin, Chief Executive Officer of BioLineRx, was quoted in the filing as stating the company "continue[s] to look forward to results from the study in the first half of next year."

The preclinical poster (EXTH-31) presented data across three orthotopic glioblastoma cell-derived xenograft studies and one subcutaneous TMZ-resistant patient-derived xenograft model. According to the filing, GLIX1 demonstrated tumor eradication and prolonged survival in the SNB19 CDX model, dose-dependent tumor growth inhibition in the U87MG CDX model, and tumor growth inhibition in the TMZ-resistant BN2276 PDX model at a point where TMZ showed no effect. Pharmacokinetic analyses in the orthotopic U87MG model confirmed brain penetration at all tested dose levels, with dose-dependent increases in tumor 5hmC correlating with tumor growth inhibition.

What Was Disclosed

BioLineRx and Hemispherian disclosed the initiation of the fourth dosing cohort in the GLIX1 Phase 1/2a study, the absence of significant adverse events, plans to add window-of-opportunity cohorts, and preclinical data showing brain penetration and antitumor activity across multiple glioblastoma models.